Cargando…

TiSe(2)-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer

BACKGROUND: Pancreatic cancer remains among the most prevalent and aggressive forms of cancer. While immunotherapeutic treatment strategies have shown some promise in affected patients, the benefits of these interventions have been limited by insufficient tumor infiltration by activated T cells. RES...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Libin, Xue, Wang, Cao, Jing, Zhang, Shengmin, Zeng, Yiqing, Ma, Ling, Qian, Xuechen, Wen, Qing, Hong, Yurong, Shi, Zhan, Xu, Youfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571469/
https://www.ncbi.nlm.nih.gov/pubmed/36243711
http://dx.doi.org/10.1186/s12951-022-01659-4
_version_ 1784810371528261632
author Chen, Libin
Xue, Wang
Cao, Jing
Zhang, Shengmin
Zeng, Yiqing
Ma, Ling
Qian, Xuechen
Wen, Qing
Hong, Yurong
Shi, Zhan
Xu, Youfeng
author_facet Chen, Libin
Xue, Wang
Cao, Jing
Zhang, Shengmin
Zeng, Yiqing
Ma, Ling
Qian, Xuechen
Wen, Qing
Hong, Yurong
Shi, Zhan
Xu, Youfeng
author_sort Chen, Libin
collection PubMed
description BACKGROUND: Pancreatic cancer remains among the most prevalent and aggressive forms of cancer. While immunotherapeutic treatment strategies have shown some promise in affected patients, the benefits of these interventions have been limited by insufficient tumor infiltration by activated T cells. RESULTS: Here, Titanium diselenide (TiSe(2)) nanosheets were synthesized with good stability. When exposed to ultrasound (US), the TiSe(2) nanosheets served as a reliable nano-sensitizer capable of inducing large amounts of reactive oxygen species (ROS) mediating sonodynamic therapy (SDT) under hypoxic and normoxic conditions. The tumor-released TAAs induced by TiSe(2) nanosheet-mediated SDT promoted immunogenic cell death (ICD) conducive to the maturation of dendritic cells (DCs), and cytokine secretion and the subsequent activation and infiltration of T cells into the tumor. Combining TiSe(2)-mediated SDT with anti-PD-1 immune checkpoint blockade treatment led to the efficient suppression of the growth of both primary tumor and distant tumor, while simultaneously preventing lung metastasis. These improved immunotherapeutic and anti-metastatic outcomes were associated with activated systematic antitumor immune responses, including the higher levels of DC maturation and cytokine secretion, the increased levels of CD8(+) T cells and the decreased levels of T(reg) cells infiltrated in tumors. CONCLUSION: TiSe(2) can be used as a sonosensitizer with good efficacy and high safety to mediate efficient SDT. The combination treatment strategy comprised of TiSe(2)-mediated SDT and PD-1 blockade activate anti-tumor immune responses effectively thorough inducing ICD, resulting in the inhibition the growth and metastasis of tumor. The combination therapy holds promise as a novel immunotherapy-based intervention strategy for pancreatic cancer patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01659-4.
format Online
Article
Text
id pubmed-9571469
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95714692022-10-17 TiSe(2)-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer Chen, Libin Xue, Wang Cao, Jing Zhang, Shengmin Zeng, Yiqing Ma, Ling Qian, Xuechen Wen, Qing Hong, Yurong Shi, Zhan Xu, Youfeng J Nanobiotechnology Research BACKGROUND: Pancreatic cancer remains among the most prevalent and aggressive forms of cancer. While immunotherapeutic treatment strategies have shown some promise in affected patients, the benefits of these interventions have been limited by insufficient tumor infiltration by activated T cells. RESULTS: Here, Titanium diselenide (TiSe(2)) nanosheets were synthesized with good stability. When exposed to ultrasound (US), the TiSe(2) nanosheets served as a reliable nano-sensitizer capable of inducing large amounts of reactive oxygen species (ROS) mediating sonodynamic therapy (SDT) under hypoxic and normoxic conditions. The tumor-released TAAs induced by TiSe(2) nanosheet-mediated SDT promoted immunogenic cell death (ICD) conducive to the maturation of dendritic cells (DCs), and cytokine secretion and the subsequent activation and infiltration of T cells into the tumor. Combining TiSe(2)-mediated SDT with anti-PD-1 immune checkpoint blockade treatment led to the efficient suppression of the growth of both primary tumor and distant tumor, while simultaneously preventing lung metastasis. These improved immunotherapeutic and anti-metastatic outcomes were associated with activated systematic antitumor immune responses, including the higher levels of DC maturation and cytokine secretion, the increased levels of CD8(+) T cells and the decreased levels of T(reg) cells infiltrated in tumors. CONCLUSION: TiSe(2) can be used as a sonosensitizer with good efficacy and high safety to mediate efficient SDT. The combination treatment strategy comprised of TiSe(2)-mediated SDT and PD-1 blockade activate anti-tumor immune responses effectively thorough inducing ICD, resulting in the inhibition the growth and metastasis of tumor. The combination therapy holds promise as a novel immunotherapy-based intervention strategy for pancreatic cancer patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01659-4. BioMed Central 2022-10-15 /pmc/articles/PMC9571469/ /pubmed/36243711 http://dx.doi.org/10.1186/s12951-022-01659-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Libin
Xue, Wang
Cao, Jing
Zhang, Shengmin
Zeng, Yiqing
Ma, Ling
Qian, Xuechen
Wen, Qing
Hong, Yurong
Shi, Zhan
Xu, Youfeng
TiSe(2)-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer
title TiSe(2)-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer
title_full TiSe(2)-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer
title_fullStr TiSe(2)-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer
title_full_unstemmed TiSe(2)-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer
title_short TiSe(2)-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer
title_sort tise(2)-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571469/
https://www.ncbi.nlm.nih.gov/pubmed/36243711
http://dx.doi.org/10.1186/s12951-022-01659-4
work_keys_str_mv AT chenlibin tise2mediatedsonodynamicandcheckpointblockadecombinedimmunotherapyinhypoxicpancreaticcancer
AT xuewang tise2mediatedsonodynamicandcheckpointblockadecombinedimmunotherapyinhypoxicpancreaticcancer
AT caojing tise2mediatedsonodynamicandcheckpointblockadecombinedimmunotherapyinhypoxicpancreaticcancer
AT zhangshengmin tise2mediatedsonodynamicandcheckpointblockadecombinedimmunotherapyinhypoxicpancreaticcancer
AT zengyiqing tise2mediatedsonodynamicandcheckpointblockadecombinedimmunotherapyinhypoxicpancreaticcancer
AT maling tise2mediatedsonodynamicandcheckpointblockadecombinedimmunotherapyinhypoxicpancreaticcancer
AT qianxuechen tise2mediatedsonodynamicandcheckpointblockadecombinedimmunotherapyinhypoxicpancreaticcancer
AT wenqing tise2mediatedsonodynamicandcheckpointblockadecombinedimmunotherapyinhypoxicpancreaticcancer
AT hongyurong tise2mediatedsonodynamicandcheckpointblockadecombinedimmunotherapyinhypoxicpancreaticcancer
AT shizhan tise2mediatedsonodynamicandcheckpointblockadecombinedimmunotherapyinhypoxicpancreaticcancer
AT xuyoufeng tise2mediatedsonodynamicandcheckpointblockadecombinedimmunotherapyinhypoxicpancreaticcancer